Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

capivasertib

(ka-PEE-vah-SER-tib)
A drug used with fulvestrant to treat adults with hormone-receptor positive, HER2-negative breast cancer that has spread and has an abnormal PIK3CA, AKT1, or PTEN gene. It is used in patients whose cancer came back or got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Capivasertib blocks a protein called AKT, which is involved in cell signaling, cell growth, and cell survival. Blocking this protein may help keep cancer cells from growing and may kill them. Capivasertib is a type of kinase inhibitor. Also called Truqap.
More Information
Search NCI's Dictionary of Cancer Terms